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The Aurora B specificity switch is required to
protect from non-disjunction at the metaphase/
anaphase transition
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The Aurora B abscission checkpoint delays cytokinesis until resolution of DNA trapped in the
cleavage furrow. This process involves PKCε phosphorylation of Aurora B S227. Assessing if
this PKCε-Aurora B module provides a more widely exploited genome-protective control for
the cell cycle, we show Aurora B phosphorylation at S227 by PKCε also occurs during mitosis.
Expression of Aurora B S227A phenocopies inhibition of PKCε in by-passing the delay and
resolution at anaphase entry that is associated with non-disjunction and catenation of sister
chromatids. Implementation of this anaphase delay is reflected in PKCε activation following
cell cycle dependent cleavage by caspase 7; knock-down of caspase 7 phenocopies PKCε
loss, in a manner rescued by ectopically expressing/generating a free PKCε catalytic domain.
Molecular dynamics indicates that Aurora B S227 phosphorylation induces conformational
changes and this manifests in a profound switch in specificity towards S29 TopoIIα phos-
phorylation, a response necessary for catenation resolution during mitosis.
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Entry to and exit from mitosis is exquisitely controlled toensure faithful propagation of the resultant daughter cells.Genome-protective pathways such as the MiDAS salvage
pathway, engaged upon the detection of incomplete DNA replica-
tion at mitosis1, or the non-disjunction response2 have evolved in
addition to cell cycle checkpoints to ensure the fidelity of division.
As a master regulator of mitosis, Aurora B has been ascribed
functions throughout mitosis and cytokinesis3. We have pre-
viously described a switch in Aurora B substrate specificity after
second site phosphorylation of the activation loop at S2274. Upon
retention of chromatin in the cytokinetic furrow an Aurora B-
dependent abscission checkpoint is engaged and protein kinase C
epsilon (PKCε) is required for exit once resolution of the lagging
DNA strands occurs. Specifically, PKCε phosphorylates Aurora B
at S227 which induces a switch in Aurora B substrate specificity,
such that it then phosphorylates the adaptor protein Borealin at
S1654 to release the ESCRTIII component CHMP4C from a
closed, inactive conformation to allow polymerisation of the
ESCRTIII complex and successful completion of abscission5,6.
PKCε-dependent pathways provide alternative, failsafe mechan-
isms for passage through mitosis. A conditional requirement for
PKCε has been reported for bipolar spindle assembly7 and the
metaphase response to catenation2 in a subset of transformed cell
lines which lack a competent topoisomerase IIα (TopoIIα)-depen-
dent G2 arrest. During metaphase, if the cell is challenged by excess
catenation, PKCε instigates a delay in anaphase entry through
delayed spindle assembly checkpoint (SAC) silencing and mitigates
dynein directed streaming of the RZZ complex2. The engagement of
PKCε in these TopoIIα-dependent G2 arrest deficient cells occurs
by an as yet, undefined mechanism.
Here we assess the penetrance of PKCε-Aurora B module
action in responding to genomic stress by addressing the
requirement at the metaphase–anaphase transition. We demon-
strate that the switch in Aurora B substrate repertoire driven by
PKCε-mediated phosphorylation of S227 during cytokinesis
appears to also function during metaphase. This correlates with
the Caspase-7 dependent proteolytic activation of PKCε. The
phosphorylation of Aurora B at S227 induces a conformational
change in the activation loop of the kinase and is required for the
switch in substrate specificity of Aurora B. This allows selection of
substrates required for satisfaction of the SAC and enhances
TopoIIα decatenation through phosphorylation of S29 promoting
sister chromatid disjunction prior to anaphase entry.
Results
Chromosome disjunction requires Aurora B S227 phosphor-
ylation. To assess the dependence on the phosphorylation of
Aurora B S227 for mitotic fidelity we introduced the non-
phosphorylatable GFP-Aurora B S227A mutant into DLD1 cells.
This results in an increase in the number of cells with aberrantly
shaped nuclei (Fig. 1a) suggesting chromosome non-disjunction
events, consistent with previous reports of an increase in
binucleate cells observed on expression of Aurora B S227A4.
There is also an increase in DAPI-positive bridges and PICH-
positive strands present in anaphase cells (Fig. 1b). This bridging
phenotype is associated with unresolved sister chromatid inter-
twines, indicative of catenation8. Direct assessment of this by
removal of centromeric cohesion through knockdown of Shu-
goshin 1 (Sgo1) (Fig. 1c), showed that a significant increase in
retained sister chromatid pairs was observed (Fig. 1d), compar-
able with knockdown of TopoIIα. We have previously demon-
strated that this association between sister chromatid pairs is
dependent on TopoIIα as post-extraction treatment of metaphase
spreads with recombinant TopoIIα results in rescue of this phe-
notype to control levels2.
A PKCε-dependent pathway responds to the retention of
metaphase catenation in transformed cells with a defective
TopoIIα-dependent G2 checkpoint2. On TopoIIα inhibition with
ICRF193, DLD1 cells delay anaphase entry and in the absence of
PKCε2 or with the expression of Aurora B S227A (Fig. 1e) this
delay is compromised, consistent with the idea that Aurora B is
operating on this pathway downstream of PKCε. In the presence
of catenation, inhibition of PKCɛ activity in a mitotically enriched
population of cells (Supplementary Fig. 1a) with either BLU577
(Fig. 1f) or BIM1 (Supplementary Fig. 1b) resulted in a significant
reduction in Aurora B S227 phosphorylation by immunoblot.
Notably, there is no change in phosphorylation of Aurora B S227
in asynchronously growing cultures treated with PKC inhibitors
(Supplementary Fig. 1c), indicating that under these conditions,
this site is phosphorylated by an as yet unidentified kinase. The
reduction in phosphorylation in mitotic extracts that we observe
with PKC inhibition shows that this PKCε-Aurora B regulatory
module is cell cycle dependent, occurring in mitosis, as well as
cytokinesis as previously described4.
Expression of the non-phosphorylatable Aurora B mutant does
not preclude the SAC response in these cells as they still mount a
checkpoint arrest in the presence of the microtubule assembly
inhibitor nocodazole (Fig. 1g). The metaphase catenation
response is characterised by MAD2low/Bub1high/BubR1high kine-
tochore staining, which is sensitive to PKCε loss or inhibition2.
After ICRF193 treatment of DLD1 cells, BubR1 is maintained at
the kinetochore in the Aurora B wild type expressing cells but not
in those expressing Aurora B S227A, accounting for the delay in
anaphase entry and bypass of the delay respectively (Fig. 1h).
Nevertheless, cells expressing Aurora B S227A mount a SAC
response in response to nocodazole inducing rapid relocalisation
of BubR1 to the kinetochore in these cells. Consistent with a
normal implementation of the SAC, MAD2 and BubR1 are
localised to the kinetochore during prometaphase in these cells,
but MAD2 is absent in metaphase cells irrespective of ICRF193
treatment or expression of Aurora B S227A (Fig. 1i).
A chromatin-associated pool of PKCε is cleaved in mitosis. We
sought to determine the mechanism by which the PKCε-Aurora B
regulatory module operates at the metaphase–anaphase transi-
tion. We find there are sub-populations of GFP-PKCε present; a
centrosomal, spindle-associated pool that we have previously
described7 as well as a chromatin-associated compartment that
can be visualised by immunofluorescence (Fig. 2a) and appears to
be enriched during metaphase. Upon fractionation of mitotic cell
extracts, it was apparent that within this latter compartment
GFP-PKCε was partially fragmented, as evident in the appearance
of two faster migrating, immunoreactive bands at 35 and 43 kDa
recognised by a C-terminal PKCε antibody (Fig. 2b). An N-
terminal cleavage fragment could be detected also by probing for
GFP (Fig. 2b). PKCε has been previously reported to be phos-
phorylated during mitosis at S346, S350, S368 to facilitate 14-3-3
binding9, resulting in slower migration of full length PKCε bands
by western blot of the TritonX-100 soluble fraction (Supple-
mentary Fig. 2a). The lower molecular weight species observed in
the insoluble fraction were verified as PKCε as these bands could
no longer be detected by western blotting after RNAi-mediated
depletion of PKCε (Supplementary Fig. 2a). We demonstrate
mitosis-specific cleavage of both endogenous (Supplementary
Fig. 2b) and exogenously expressed (Supplementary Fig. 2c)
PKCε across multiple cell lines, indicating that this is a wide-
spread event. Some cleavage of PKCε is evident in asynchro-
nously cycling cells and we attribute this observation to the
presence of mitotic cells in these cultures. The observed cleavage
of PKCε is chromatin associated (Supplementary Fig. 2d) and
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mitosis specific, evidenced by an enrichment of these cleavage
products in prometaphase synchronised cells (Supplementary
Fig. 2e). Enrichment in G1/S or G2 phase did not yield these
faster migrating cleaved species (Supplementary Fig. 2f). Inhibi-
tion of PKCε using the selective inhibitor BLU5772,4,10 did not
influence proteolytic cleavage nor did inhibition of TopoIIα,
known to engage a PKCε dependent mitotic pathway2 (Supple-
mentary Fig. 2g). The fragment produced is characterised by
phosphorylation on key priming sites and these modifications are
essential for catalytic competence (Supplementary Fig. 2h)11.
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Non-canonical Caspase-7 cleavage of PKCε. Previously, PKCε
has been reported to be cleaved by Caspase-7 in vitro and this is
associated with a pattern of fragmentation consistent with that
observed here12. The sites of cleavage were mapped to D383,
located in the V3 hinge region, and D451, in the α-C helix of the
kinase domain (see schematic, Fig. 2c). The consequence of
cleavage at the D383 site is the liberation of a free kinase domain
which relieves PKCε from auto-inhibition. We therefore sought
to examine whether this was the mechanism of cell cycle-
dependent PKCε cleavage in vivo. Cleavage of PKCε to the 43
kDa free kinase domain was significantly inhibited by treatment
of cells with the pan-Caspase inhibitor z-vad-FMK (Supplemen-
tary Fig. 3a). Knockdown of Caspase-7 resulted in a 64% reduc-
tion of the cleaved, TritonX-100 insoluble PKCε species, however
no significant reduction in cleavage was observed with depletion
of Caspase-3 (Fig. 2d), suggesting a predominantly Caspase-7
dependent pathway, in agreement with observations by Basu
et al.12. We note here, that the cleavage is not an equilibrium
event it is unidirectional, hence it is difficult to achieve a more
penetrant blockade as the residual activity ratchets towards
cleavage.
We observed no evidence of an apoptotic programme being
triggered associated with or consequent to Caspase-7 cleavage of
PKCε. Treatment of cells with ICRF193 or nocodazole did not
affect cell viability (Supplementary Fig. 3b) nor did it induce
cleavage of the apoptotic marker, poly (ADP ribose) polymerase
(PARP) (Supplementary Fig. 3c). We observe cleavage of
Caspase-7 to its active form in cells arrested in prometaphase
but not those enriched in G1/S or G2 phases (Supplementary
Fig. 3d).
We then investigated whether the Caspase-7-dependent
cleavage of PKCε was required to sustain the metaphase
catenation response. It was found that Caspase-7 knockdown
led to a substantial loss of the metaphase delay (Fig. 2e), similar to
that observed with expression of the Aurora B S227A mutant
(Fig. 1e). Importantly, this was rescued by the expression of the
kinase domain of PKCε indicating that this is the necessary
pathway operating under the control of Caspase-7 (Fig. 2f).
Collectively the data indicate an apoptosis-independent role
for Caspase-7 of which PKCε is the critical target in this cell
cycle pathway and that cleavage of PKCε to release the kinase
domain is required for the ICRF193-induced delay in the
metaphase–anaphase transition.
PKCε cleavage protects from chromosome non-disjunction.
Mutation of the aspartate residues identified as Caspase-7
cleavage sites by Basu et al.12 to asparagine, demonstrated that
these are also the sites of mitotic cleavage (Fig. 3a). The expressed
cleavage-site mutants were phosphorylated on the PKCε priming
sites indicating that loss of catalytic competence did not appear to
underlie the non-cleavage (Supplementary Fig. 4a, b). We then
assessed the biological significance of this active catalytic frag-
ment of PKCε that had been cleaved at D383 and in particular its
potential role in the metaphase catenation-associated cell cycle
delay, since we know that this pathway shows dependence on
PKCε.
We engineered a DLD1 cell line to express inducible, GFP-
tagged PKCε where the cleavage sites have been mutated
(Supplementary Fig. 4c). Endogenous PKCε is depleted in
experiments where GFP-PKCε is induced to ensure results are
not confounded by the dominant behaviour of the cleaved
fragment. These cell lines were characterised and expression of
the GFP-PKCε mutants does not affect the SAC (Supplementary
Fig. 4d) nor induce PARP cleavage (Supplementary Fig. 4e),
further suggesting the observed cleavage of PKCε was indepen-
dent of a pro-apoptotic role of Caspase-7. By blocking the
cleavage at D383 (with or without a block to cleavage at D451),
we observed an increase in the number of cells exhibiting
aberrantly shaped nuclei (Fig. 3b). Loss of cleavage was also
associated with an increase in both DAPI-positive chromosome
bridges and PICH-positive strands, indicative of chromosome
non-disjunction errors (Fig. 3c), phenocopying Aurora B S227A
expression. Furthermore, cleavage of PKCε was required to
support resolution of catenation (Supplementary Fig. 4f), as the
non-cleavable PKCε failed to promote resolution of catenation in
metaphase (Fig. 3d). We cannot conclusively exclude the presence
of ultra-fine bridges or retention of cohesin as a contributing
cause of sister chromatid non-disjunction due to technical
limitations of available reagents; however, the presence of non-
disjoined sister chromatids was rescued in vitro with recombinant
TopoIIα, as we have demonstrated previously2. The increment of
retained sister chromatid pairs that is reversed by treatment with
recombinant TopoIIα in vitro provides a robust functional assay
for the extent of association dependent upon catenation. This is
certainly not 100% of all non-disjunction events which may
indeed include other modes of sister chromatid association such
as a cohesin-removal defect13,14, but these are not impacted by
the PKCε-Aurora B pathway reported here.
The metaphase catenation response requires cleaved PKCε. In
cell lines where cleavage to the free kinase domain was prevented
(D383N and D383/451N mutants), a loss of the characteristic
Fig. 1 Phosphorylation of Aurora B S227 is required to support the metaphase response to catenation. a DLD1 cells expressing GFP-Aurora B wild type or
S227A were scored for nuclear morphology. The mean ± SD of three independent experiments is graphed (n=≥200) (one-way ANOVA, *P=≤0.024; Control
6.76% ± 1.46, WT 11.76% ± 5.63, S227A 27.63% ± 10.07). Scale bar= 5 μm. b Anaphase cells were scored for DAPI-positive bridges or PICH-positive
strands. The graph represents the mean ± SD of three independent experiments, >20 cells per condition were scored per experiment (two-tailed Students’ t test,
*P=0.027, DAPI: WT 10.35% ± 7.49, S227A 46.02% ± 25.62, PICH: WT 17.18%± 14.8, S227A 35.98%± 15.83). Scale bar= 5 μm. c Representative images of
single sister chromatids or retained/catenated sister chromatids after 24 h Shugoshin knockdown (siSgo). Scale bar= 2 μm. d Cells were scored for the
percent retained (catenated) sister chromatids. The mean ± SEM of three experiments where ≥15 cells per experiment were analysed is graphed (one-way
ANOVA; **P=0.0061; siControl 47.05%± 5.75, siTopoIIα 78.84 ± 6.61, WT 46.23 ± 4.13, S227A 83.21 ± 5.561). Scale bar= 5 μm. e DLD1 cells expressing
GFP-Aurora B wild type or S227A were treated ± 1 μM ICRF193 immediately prior to time-lapse imaging and scored for time from metaphase to anaphase.
Violin plots represent all cells scored, median in red. A minimum of 100 cells per condition in three independent experiments were analysed. (one-way ANOVA;
****P=≥0.0001). f Immunoblot of DLD1 cells (representative of three independent experiments) enriched in mitosis and treated with ICRF193 (1 µM) ±
BLU577 (500 nM). TritonX-100 insoluble fractions were probed for Aurora B phospho-S227, total Aurora B, and TopoIIα. Mean ± SD of the immunoblots is
graphed (two-tailed Students’ t test; **P=0.001;+ICRF/+BLU 0.5835 ± 0.085). g Cells were treated with 500 nM nocodazole and imaged using live-cell time-
lapse microscopy for 24 h and scored for their time arrested in mitosis. The mean ± SD of three experiments where >50 cells were analysed per condition, per
experiment are graphed. Representative images of (h) BubR1 and (i) MAD2 kinetochore localisation after inducing a metaphase delay with ICRF193 (4 h, 1 µM)
± BLU577 (20min 500 nM) or ±nocodazole (5min, 500 nM), from three independent experiments, a minimum of ten images were acquired. DAPI (blue),
GFP-Aurora B (green), BubR1/MAD2 (magenta), CREST (white). Scale bar= 5 μm.
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ICRF193-induced delay to anaphase entry was observed (Fig. 3e).
To assess whether the cleavage product of PKCε is sufficient to
support the metaphase functions of PKCε, we expressed the PKCε
kinase domain in cells where the endogenous PKCε had been
depleted (Fig. 3f, Supplementary Fig. 4g). Interestingly, the cat-
alytic domain of PKCε is sufficient to maintain both the catenane
resolution pathway (Supplementary Fig. 4f) and the ICRF193-
induced delay to anaphase entry (Fig. 3f). The cleavage product
was able to fully recover PKCε functionality in both pathways
after siRNA knockdown and there was no change to the meta-
phase duration or the number of catenated sister chromatids
compared with the control. This suggested an essential role for
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PKCε catalytic fragment production in execution of both the
catenation-associated metaphase delay and also a catenation
resolution pathway.
To address any potential confounding effect associated with the
prolonged, constitutive expression of this kinase domain, we
established expression of a rapamycin-inducible TEV-cleavage
mutant of PKCε that permitted timed cleavage of the protein
(Fig. 3g, h)15,16. As for the constitutively expressed kinase
domain, metaphase induced cleavage was able to support the
delay to anaphase entry (Fig. 3i). Hence the cell cycle associated
cleavage of PKCε to generate an active kinase domain is sufficient
for the implementation of these metaphase–anaphase transition
controls and reveals a Caspase-7-dependent PKCε-Aurora B
signalling module.
Aurora B switches specificity to modify two sites on TopoIIα.
TopoIIα has been identified as a classical PKC substrate in pre-
vious studies17–19 and this was determined to be a cell cycle phase
specific phosphorylation of the residue S2918. We generated a
phospho-specific antibody against this site to determine whether
TopoIIα S29 could be a target of signalling through the mitosis-
derived PKCε catalytic fragment. Phosphorylation of TopoIIα at
S29 was observed to be most prevalent during metaphase and to a
lesser extent during anaphase; however it is completely absent at
cytokinesis and in non-mitotic cells (Fig. 4a). Phosphorylation of
S29 was significantly reduced after PKCε inhibition with BLU577
(Fig. 4b). Strikingly, TopoIIα S29 phosphorylation was sub-
stantially more reduced after Aurora B inhibition with ZM447439
(Fig. 4b), suggestive of TopoIIα being a downstream target of the
PKCε-Aurora B signalling module.
A direct relationship between Aurora B and TopoIIα has also
previously been described20. In agreement with the observations
of Coelho et al., we detect co-localisation of Aurora B and
TopoIIα at the centromere in metaphase cells (Supplementary
Fig. 5a). The centromeric localisation of TopoIIα was lost upon
Aurora B knockdown and became more diffuse with expression
of Aurora B S227A suggesting a functional relationship with the
PKCε-Aurora B node. We sought to determine whether active
Aurora B (both the pT232 and the pS227/pT232 phosphorylated
forms) could phosphorylate TopoIIα initially using peptide arrays
of the protein (Fig. 4c, d). Remarkably, the two phospho-species
of Aurora B displayed distinct preferences for the phosphoryla-
tion of TopoIIα. The recombinant Aurora B wild type protein
(pS227/pT232) predominantly phosphorylated TopoIIα S29 while
the Aurora B S227A mutant (only phosphorylated on T232 in the
activation loop) chiefly phosphorylated the T1460 site (Fig. 4c, d).
This preference in substrate sites was also displayed in the
phosphorylation of recombinant TopoIIα in vitro (Fig. 4e,
Supplementary Fig. 5b). We further validated these as being
bona fide, cell cycle regulated phosphorylation sites in cells by
immunoblot and immunofluorescent microscopy (Supplemen-
tary Fig. 5c–f). Notably, we confirmed TopoIIα S29 as a substrate
of the PKCε-Aurora B signalling module in cells as phosphoryla-
tion at this site is significantly diminished upon expression of
either the non-cleavable PKCε D383/451N or Aurora B S227A
(Fig. 4f, g).
Detection of phosphorylation at TopoIIα T1460 was con-
founded by the fact that the phospho-T1460 antibody alone was
not amenable to standard immunofluorescent staining methods,
however detection by proximity ligation assay (PLA) when paired
with a pan-TopoIIα antibody allowed visualisation of the
localisation of T1460-phosphorylated TopoIIα. Phosphorylation
of the T1460 site appears to occur in both mitotic and non-
mitotic cells to varying degrees but nevertheless dependent on
Aurora B as the PLA signal is diminished upon treatment with
ZM447439 (Supplementary Fig. 5f). We validated the signal from
the antibody pairs by peptide competition and were no longer
able to detect signal in the presence of peptide with the
phosphorylated-T1460 residue (Supplementary Fig. 5f).
Aurora B S227 influences activation loop dynamics. The pro-
found switch in Aurora B specificity towards TopoIIα led us to
examine the differences in the predicted kinase structure and the
dynamics underlying the switch in Aurora B substrate specificity
using molecular dynamics simulations. A 100 ns molecular
dynamics simulation was carried out to explore the role of
phosphorylation of Aurora B pS227 on the dynamics of the
protein and the conformation of the activation loop. The simu-
lations were carried out in the ATP-bound form and in the
presence of the INCENP C-terminal domain. During the course
of the MD simulation, the loop region of the Aurora B pT232
form appeared to be more flexible than the Aurora B pS227/
pT232 form (Supplementary Fig. 6a). Principal component ana-
lysis (PCA) highlights that the conformation of the loop in
Aurora pS227/pT232 is noticeably different from the loop in
Aurora B pT232. The RMSF fluctuations of PC1, PC2, and
PC3 show different dynamics in the pS227/pT232 form of Aurora
B as well as a change in motion in the activation loop and
INCENP (Supplementary Fig. 6b).
The dominant conformations of the pT232 and pS227/pT232
Aurora B enzymes (Supplementary Fig. 6c), extracted from the
MD trajectories, were used for the molecular docking of peptides
containing TopoIIα S29 and T1460 residues to assess the switch
in substrate specificity observed for the pT232/pS227 Aurora B
enzyme. The peptide containing TopoIIα S29 was able to bind to
the groove in C-lobe of the protein structure next to the ATP-
binding pocket of the dominant form of pS227/pT232 Aurora B
but the monophosphorylated pT232 Aurora B dominant form
could not accommodate the peptide. Similarly, the peptide
containing T1460 residue docked within the binding pocket close
to the ATP-binding site of pT232 Aurora B. However, this
peptide occupied a much lower position and with inappropriate
orientation in the pS227/pT232 Aurora B. The peptide docking
was followed by 100 ns MD simulations to further explore the
Fig. 2 A chromatin-associated pool of PKCε is cleaved by Caspase-7 in mitosis. a Pre-extraction of cells with 0.1% Triton X-100 prior to fixation revealed
a chromatin-associated pool of PKCε. Images are representative of three independent experiments. Scale bar= 5 μm. b Triton X-100 insoluble fraction of
asynchronous or nocodazole (500 nM) arrested DLD1 cell lysates were probed for PKCε, GFP, and Histone H3. Western blot is representative of three
independent experiments. c Schematic of PKCε domains and cleavage products with putative cleavages sites described by Basu et al.12 marked by red
arrows. d Immunoblot of GFP-PKCε to assess cleavage after knockdown of Caspases 3 and 7. Graph denotes the mean ± SD of three independent
experiments where the proportion of cleaved 43 kDa fragment of PKCε present in the immunoblots was determined by densitometry (two-tailed Students’
t test; **P= 0.01; siControl 20.85 ± 0.76, SiCas3 13.9 ± 6.38, siCas7 7.4 ± 4.95, siCas3+ siCas7 8.98 ± 4.37). DLD1 cells were depleted of Caspase-7 and
induced to express (e) GFP-PKCε wild type or (f) GFP-PKCε kinase domain and assessed for their response to metaphase catenation. Cells were
treated with ±1μM ICRF193 immediately prior to time-lapse imaging and scored for the time to progress from metaphase to anaphase. Violin plots
represent all cells scored, the median is in red. A minimum of 100 cells per condition in three independent experiments were analysed. (One-way ANOVA,
****P=≤0.0001). Caspase-7 knockdown was confirmed by immunoblot for each experiment.
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interactions between the peptides and the critical residues of the
enzyme. As the catalytic mechanism of Aurora B involves
acidifying the incoming OH of the substrate by aspartic acid of
HRD motif, the distance between Asp200 of the motif and the
OH group of TopoIIα S29 and T1460 residue was monitored
throughout the course of the simulation. The initial distance for
the pT232 substrate T1460 residue was 10.768 Å—the MD
simulation then pulled the substrate peptide closer to the ATP
site, and the distance was reduced to 4.203 Å (Supplementary
Fig. 7a, b). A similar phenomenon was observed for the pT232/
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pS227 substrate peptide TopoIIα S29, and the distance was
reduced from 12.948 to 4.666 Å (Supplementary Fig. 7a, b). The
post-simulation distances suggest the OH of the substrate peptide
is in close proximity of the Asp200 to initiate the catalytic cycle.
However, in the case of TopoIIα S29 and pT232 Aurora B, and
T1460 and pS227/pT232 Aurora B, the distances, both pre-and
post-simulations, remained unfavourable for phosphorylation to
occur (Supplementary Fig. 7c) and the orientation of the peptides
remained unfavourable.
Aurora B phosphorylation of TopoIIα enhances decatenation.
To examine the potential function of these Aurora B sites on
TopoIIα, we engineered the DLD1 cell line to express inducible
GFP-TopoIIα with the S29 and T1460 residues mutated to non-
phosphorylatable alanine, both individually and in combination
(Supplementary Fig. 8a). Interestingly, neither site mutant nor their
combination influenced the implementation of a delay to anaphase
entry in the presence of ICRF193 (Fig. 5a) suggesting a function for
Aurora B and the phosphorylation of TopoIIα distinct from the
regulation of the SAC (see above Fig. 1g, h and ref. 2). We next
investigated whether the two distinctive forms of Aurora B would
influence the activity of recombinant TopoIIα in vitro. To ensure
we could observe any effect of Aurora B phosphorylation,
recombinant TopoIIα was titrated to sub-optimal decatenation
activity (Supplementary Fig. 8b). Aurora B WT protein (pS227/
pT232) increased TopoIIα activity against catenated kinetoplast
DNA, while the S227A mutant (i.e., not phosphorylated at S227)
showed a reduced effect (Fig. 5b) despite both kinase preparations
demonstrating comparable activity against the shared substrate,
Histone H3 S10 (Supplementary Fig. 8c)4. This strongly suggests
that phosphorylation of TopoIIα at the S29 site contributes to the
resolution pathway. Further supporting this is the observation
that in vivo, when decatenation is inhibited with ICRF193,
phosphorylation at the S29 site persists beyond mitosis, into
cytokinesis as well as being present in binucleated cells that have
failed cytokinesis (Fig. 5c). To further explore the requirement for
phosphorylation at these sites, we used the inducible DLD1 GFP-
TopoIIα cell lines and also engineered HEK293 cells to express
inducible GFP-TopoIIα WT or mutant forms with either the
single or paired sites compromised: S29A, T1460A, and S29/
T1460A (Supplementary Fig. 8d). We found that unlike the
ectopic WT TopoIIα, mutant forms in either of these two phos-
phorylation sites prevented support of the resolution pathway and
led to the accumulation of catenated chromosomes (Fig. 5d, e); in
cells where S29 was unable to be phosphorylated, this was com-
mensurate with an increase in cells with aberrant nuclear mor-
phology (Supplementary Fig. 8e). GFP-TopoIIα was extracted
from the inducible HEK293 cell lines (Supplementary Fig. 8f) to
examine whether the non-phosphorylatable mutant TopoIIα
could still decatenate kDNA in vitro. We demonstrate a dimin-
ished decatenation ability of both TopoIIα S29 mutants (S29A
and S29/T1460A) (Supplementary Fig. 8f, g) indicating phos-
phorylation of TopoIIα S29 enhances the decatenating ability of
the enzyme. Collectively, the data indicate a bifurcation of the
described Caspase7-PKCε-Aurora B pathway (Fig. 6). One arm of
this pathway signals a delay in anaphase entry through PKCε-
Aurora B regulation of SAC silencing in response to unresolved
catenanes, whilst the other directly influences the behaviour of
TopoIIα in relation to the resolution of catenation through S29
phosphorylation.
Discussion
We have defined a mechanism by which the key mitotic kinase,
Aurora B, orchestrates safe passage through the
metaphase–anaphase transition in the presence of catenation. The
switch in Aurora B substrate repertoire after PKCε phosphorylation
of the activation loop residue S227 has profound effects on con-
formation of the kinase and how it interacts with substrates. This
was demonstrated by the distinct difference in preference between
Aurora B phosho-species for the two phosphorylation sites on
TopoIIα, S29, and T1460, and we identified S29 phosphorylation as
being necessary for enhanced catenation resolution. In addition, we
have determined the input upstream of Aurora B which involves a
non-canonical Caspase-7 signalling pathway resulting in the pro-
teolytic cleavage of PKCε in mitosis. This effectively disengages the
kinase from the well-defined mechanism of activation initiated by
lipid binding at the cell membrane, potentially allowing PKCε
access to the chromatin compartment and Aurora B. The data
describe a novel signalling cascade engaging a genome-protective
module, the PKCε-Aurora B cascade, acting both to delay meta-
phase in response to catenation and to promote resolution of
catenation present in metaphase.
Fig. 3 Cleaved PKCε is required for the metaphase catenation response. a Immunoblot of the TritonX-100-insoluble fraction of DLD1 cells expressing
GFP-PKCε cleavage-site mutants, after arrest with nocodazole (500 nM) ± ICRF193 (1 μM) (representative of three independent experiments).
b DLD1 cells expressing GFP-PKCε wild type or cleavage mutants were scored for nuclear morphology. The mean ± SD of three independent experiments is
graphed (n=≥200 cells per condition, per experiment, two-tailed Students’ t test; *P= 0.023, **P= 0.008; siPKCε 22.11% ± 3.68, WT 11.4% ± 1.21,
D383N 29.4% ± 8.64, D451N 12.85% ± 5.94, D383/451 N 28.53% ± 3.43). c Anaphase DLD1 cells expressing GFP-PKCε wild type or D383/451N were
scored for DAPI-positive bridges or PICH-positive strands. The mean ± SD of three independent experiments is graphed (n=≥20 cells per condition, per
experiment) (two-tailed Students’ t test, *P= 0.012, DAPI:WT 27.33% ± 2.52, D383/451N 35.06% ± 1.761, PICH: WT 19% ± 6.93, D383/451N 53.01% ±
11.88). d Cells scored for the percent retained (catenated) sister chromatids. The mean ± SEM of three independent experiments is graphed (n=≥15 cells
per experiment) (One-way ANOVA; **P=≤0.0064; WT 44.24% ± 5.74, D383/451N 76.43% ± 2.36, D383/451N+ rTopoIIa 34.4% ± 5.83) Scale bar= 5
μm. e DLD1 cells expressing GFP-PKCε wild type or cleavage mutants were treated ± 1 μM ICRF193 immediately prior to time-lapse imaging and scored for
metaphase-to-anaphase transition time. Violin plots represent all cells scored. A minimum of 50 cells per condition in three independent experiments were
analysed (One-way ANOVA, ****P=≤0.0001; WT+ ICRF193 46.26 ± 4.62min, D383N+ ICRF193 25.51 ± 1.32min, D451N+ ICRF193 48.9 ± 1.18 min,
D383/451 N+ ICRF193 23.05 ± 1.62min). f DLD1 cells expressing GFP-PKCε wild type, cleavage mutants or kinase domain were treated ±1 μM ICRF193
immediately prior to time-lapse imaging and scored for metaphase-to-anaphase transition time. Violin plots represent all cells scored. A minimum of 50
cells per condition in three independent experiments were analysed. (one-way ANOVA; ****P=≤0.0001; siPKCε+ ICRF193 24.05 ± 1.15 min, WT+
ICRF193 55.71 ± 2.3 min, D383/451N+ ICRF193 24.92 ± 2.46min, kinase domain 55.01 ± 2.6 min). g Schematic of split-TEV system. h Immunoblot
(representative of three independent experiments) of DLD1 cells co-expressing GFP-PKCεD383/451N ± TEV recognition sequence and split-TEV (sTEVp)
after ± rapamycin (100 nM) for 3 and 6 h to demonstrate TEV-dependent cleavage. i DLD1 cells expressing GFP-PKCε wild type or TEV-cleavage mutant
were arrested with nocodazole (3 h, 500 nM) followed by ± rapamycin (2 h,100 nM). After nocodazole washout cells were treated ±1μM ICRF193
immediately prior to time-lapse imaging and scored for metaphase-to-anaphase transition time. Violin plots represent all cells scored. A minimum of 100
cells per condition in three independent experiments were analysed (one-way ANOVA; ****P=≥0.0001; WT+ ICRF193 47.15 ± 0.82min, WT+ ICRF193
+ Rapamycin 47.86 ± 0.9min, D383/451NTEV+ ICRF193 25.25 ± 1.15 min, D383/451NTEV+ ICRF93+ Rapamycin 44.95 ± 1.35min).
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At the later abscission checkpoint, PKCε is activated by 14-3-3
binding9 and this is associated with Aurora B phosphorylation at
S227 in the activation loop, causing a switch in substrate specificity
and Borealin phosphorylation at S1654. A protective role of PKCε at
the abscission checkpoint is similarly the case at the
metaphase–anaphase transition. In the presence of TopoIIα inhi-
bition at metaphase, PKCε delays silencing of the SAC and ana-
phase entry by modulating dynein-mediated streaming of BubR1
away from the kinetochore2. This suggests that signalling through
this pathway is important in both the resolution of metaphase
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catenation and delayed onset of anaphase. The ability of Aurora B
S227A to phenocopy PKCε mutant behaviour is consistent with
previous data indicating that Aurora B S227 is a substrate of the
recombinant PKCε kinase domain influencing substrate selection of
Aurora B4. We herein provide direct evidence of PKCε phosphor-
ylation of Aurora B S227 in mitosis, demonstrating that a PKCε-
Aurora B signalling module plays a protective role at both cell cycle
junctures.
We have previously reported the ability of Aurora B to switch
substrate specificity in response to PKCε phosphorylation to exit
from the abscission checkpoint4. MD simulations suggest the
phosphorylation of S227 makes a significant conformational
change in the loop structure and the dynamics of the protein.
This change in dynamics can potentially explain the changes in
the substrate specificity compared with the constitutively active
Aurora B pT232. This was supported by peptide docking fol-
lowed by the 100 ns MD simulation of the TopoIIα S29 peptide-
bound Aurora B pS227/pT232 and the T1460 residue containing
peptide-bound Aurora B pT232. The complexes remained stable
throughout the course of the simulation. The bis-
phosphorylated B pS227/pT232 Aurora B could not accom-
modate the peptide containing T1460 residue while being able to
accommodate the TopoIIα S29 peptide, the reciprocal is also
true, providing further insight into the substrate switch. During
the MD simulations, the phosphorylated forms of Aurora B
were able to pull their respective substrate peptides towards the
nucleotide-binding site and close to D200 to align for catalysis.
This indicates that the changes in conformation of the kinase
after phosphorylation of S227 are directly related to the selection
of distinct substrates.
Cleavage by Caspase-7 proteolysis in the V3 hinge domain of
PKCε, resulted in a small pool of constitutively active kinase
domain. Other PKC family members including PKCδ, PKCη,
PKCθ are similarly cleaved by Caspase in the V3 hinge region to
separate the regulatory domain and catalytically active kinase
domain21; however these responses are pro-apoptotic signals. The
outcome of Caspase-7 cleavage of PKCε appeared to be different
as we observed no evidence of an apoptotic programme being
triggered. In fact, Basu et al. report that Caspase-7 dependent
cleavage of PKCε in MCF7 cells protects from TNF-induced
apoptosis12. Caspase-7 has been implicated in mitotic progres-
sion; expression of the active form of the protease increases
during mitosis and knockdown or inhibition of Caspase-7 in
HepG2 cells prevents proliferation by arresting cells in mitosis22.
This non-apoptotic role of Caspase-7 in mitosis is supported by a
growing body of literature of alternative functions of Caspases
including cell cycle regulation where, for example, Caspase clea-
vage of proteins such as p21CIP1/WAF123, p27KIP124,25, and
BubR126 have been reported to drive proliferation. Collectively
the data indicate that PKCε is the critical target for Caspase-7 in
this non-disjunction protective cell cycle pathway and that clea-
vage of PKCε to release the kinase domain is necessary and
sufficient for the delay in the metaphase–anaphase transition as
well as resolution of the catenation associated with this delay.
The mapping of the Caspase-7-PKCε-Aurora B cascade led us to
test whether the catenane resolution pathway is directly influenced
by the output of this cascade. TopoIIα mediates decatenation and
has been identified previously as both a PKC substrate17,18, and an
Aurora B substrate in vitro27 and a functional relationship between
the two kinases and TopoIIα has been described in yeast (PKC17,
Aurora B28) and Drosophila20. While we cannot exclude PKCε as
an upstream kinase which phosphorylates TopoIIα, inhibition with
ZM447439 and expression of the Aurora B S227A mutant suggests
this phosphorylation is predominantly carried out by Aurora B.
PKCδ, which is also cleaved by caspases to generate a free catalytic
domain, modulates TopoIIα activity in S phase in response to
genotoxic stress, triggering Caspase-dependent apoptotic cell
death29. Interestingly, Coelho et al.20 report that Aurora B locali-
sation and activity at the centromere is dependent on the presence
of TopoIIα for accurate bi-orientation and chromosome segrega-
tion. Further to this, Edgerton et al.28 demonstrated that Aurora B
is recruited by the C-terminal domain of TopoIIα, independent of
the enzyme’s catalytic activity. We demonstrate that TopoIIα is a
direct substrate of Aurora B and phosphorylation of TopoIIα
enhances the decatenating ability of the enzyme required for the
resolution pathway, however this interaction is independent of the
catenation-associated delay to anaphase entry. Taken together, the
data indicate a bifurcation of the described Caspase-7-PKCε-Aurora
B pathway. One arm of this pathway signals a delay in anaphase
entry through PKCε-Aurora B regulation of SAC silencing at the
kinetochore in response to unresolved catenanes, whilst the other
triggers phosphorylation of TopoIIα impacting catenane resolution.
In summary, the unravelling of the catenation-associated delay
and resolution pathways operating through PKCε at the meta-
phase/anaphase transition, has revealed a series of distinctive
events. There is a non-canonical, cell cycle coupled activation
pathway operating through Caspase-7 resulting in PKCε cleavage.
This produces a phosphorylated i.e., primed, catalytic domain
which we demonstrate by ectopic expression and inducible PKCε
cleavage, is sufficient to implement the delay to anaphase entry
triggered by ICRF193 treatment. Having previously established
that Aurora B can be a downstream target of PKCε, we demon-
strate here that the ability of Aurora B to switch substrate
repertoire in response to phosphorylation at S227 is important for
both the delay and resolution pathways. We provide evidence that
two phospho-forms of Aurora B differentially phosphorylate
Fig. 4 Aurora B switches substrate specificity to phosphorylate TopoIIα. a Immunofluorescent images of DLD1 cells stained for TopoIIα phospho-S29
(magenta), a-tubulin (green) and DNA (blue). Images are representative of three independent experiments. Scale bar= 5 μm. b Representative still images of
DLD1 cells stained with TopoIIα pS29 (magenta), a-tubulin (green) and DNA (blue) after 30min treatment with the PKCε inhibitor BLU577 (500 nM) or 15min
Aurora B inhibition with ZM447439 (2 μM). Quantification of integrated pixel intensity measurements of TopoIIα pS29. Graph shows mean ± SEM of three
experiments where 20 cells were scored per condition (one-way ANOVA; **P=0.0034 ****P=≤0.0001; Control 1 ± 0, BLU577 0.5967 ± 0.08, ZM447439
0.18 ± 0.04) Scale bar= 5 μm. c Peptide array (n= 1) of full length TopoIIα with recombinant Aurora B wild type (top panel) or Aurora B S227A (lower panel).
d Quantification of TopoIIα array spot intensity for S29 and T1460 peptides. Graph represents mean ± SD of the intensity of spots highlighted in red in c (n=
3 spots for S29, n= 4 spots for T1460). (two-tailed Students’ t test; ****P= 5.17 × 10−6(S29), P= 1.4 × 10−8 (T1460); S29: Aurora B WT 1.45 ± 0.34, S227A
0.12 ± 0.03, T1460: WT 0.2 ± 0.05, S227A 1.47 ± 0.13). Spot densitometry analysed by ImageJ software. e In vitro kinase assay of TopoIIα with Aurora B wild
type or S227A kinase. TopoIIα was immunoblotted for phosphorylation at residues S29 and T1460. Immunoblot is representative of four independent
experiments. f Representative images of DLD1 cells induced to express GFP-PKCε WT or D383/451N mutant stained for TopoIIα pS29 (magenta) and tubulin
(green). Quantification of integrated pixel intensity measurements of TopoIIα pS29. Graph shows mean ± SEM of three experiments where ≥20 cells were
scored per condition (two-tailed Students’ t test; **P=0.009) Scale bar= 5 µm. g Representative images of DLD1 cells induced to express GFP-Aurora BWT or
S227A mutant stained for TopoIIα pS29 (magenta) and GFP-Aurora B (green). Quantification of integrated pixel intensity measurements of TopoIIα pS29.
Graph shows mean ± SEM of three experiments where ≥10 cells were scored per condition (two-tailed Students’ t test; ***P=0.0008) Scale bar= 5 µm.
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TopoIIα to directly affect its activation, specifically acting in the
resolution pathway (Fig. 6).
Methods
Reagents. All reagents were purchased from Sigma-Aldrich unless otherwise stated.
BLU577 was kindly provided by Dr Jon Roffey, Cancer Research Technology, UK.
Cell culture. All cell lines were obtained from ATCC and cultured in DMEM
(Thermo Fisher Scientific) with 10% fetal calf serum (Thermo Fisher Scientific).
Tetracycline-inducible DLD1 (a kind gift from Prof Stephen Taylor, University of
Manchester) were generated using the Flp-In™ T-Rex™ system (Invitrogen)
according to the manufacturer’s instructions. For GFP-Aurora B, GFP-TopoIIα or
GFP-PKCε expression, cells were depleted of endogenous protein by siRNA and
cultured in DMEM containing 10% FCS and tetracycline (100 ng/ml) for 16 h prior
– + + + +– – – ICRF-193
GFP-
TopoIIα
WT S29A T1460A S29A/
T1460A
Metaphase
Cytokinesis
DAPI
+
 IC
R
F-
19
3 
α-tubulin
TopoIIα-
pS29
Binucleate
a b
c
d e
La
dd
er
Xh
o1
 
kD
N
A
0.1U 
TopoIIα
WT S227A
+ ++
Aurora B
ns
DLD1 HEK293
0
50
100
****
ns
Aurora B
TopoIIα WT S227A
0.0
0.1
0.2
0.3
D
ec
at
en
at
ed
 k
DN
A 
(A
U)
** *
150
0
50
100
M
et
ap
ha
se
-to
-a
na
ph
as
e
tra
ns
itio
n 
tim
e 
(m
in)
WT S29A T1460A  S29A/
T1460A
GFP-TopoIIα
Control siTopoIIα WT S29A T1460A  S29A/
T1460A
GFP-TopoIIα
Control siTopoII αR
et
ai
ne
d 
sis
te
r c
hr
om
at
id
 p
ai
rs
 (%
)
R
et
ai
ne
d 
sis
te
r c
hr
om
at
id
 p
ai
rs
 (%
)
0
50
100
ns
*
8
6
5
3
4
2
10
1.5
1
kb
Fig. 5 Phosphorylation is required for enhanced TopoIIα decatenation. a DLD1 cells induced to express GFP-TopoIIa wild type or mutants were assessed
for the metaphase catenation response. Cells were treated ±1 μM ICRF193 immediately prior to time-lapse imaging and scored for the time to progress from
metaphase to anaphase. The mean ± SEM of three independent experiments is represented by the graph, ≥100 cells per condition were analysed. (one-way
ANOVA; WT+ ICRF193 55.6 ± 2.23min S29A+ ICRF193 44.18 ± 6.69min, T1460A+ ICRF193 46.11 ± 2.77min, S29/T1460A+ ICRF193 45.52 ± 1.71 min).
b In vitro decatenation assay. Quantification of the amount of decatenated kDNA present after addition of TopoIIα and recombinant Aurora B (wild type or
S227A). Graph represents the mean ± SD of five independent experiments. (two-tailed Students’ t test, *P= 0.012, **P= 0.0025; Control 0.024 ± 0.009,
WT 0.208 ± 0.06, S227A 0.132 ± 0.05). c Representative immunofluorescence images of DLD1 cells after 1 h treatment with ICRF193 (1 μM) showing
TopoIIα pS29 (magenta), a-tubulin (green) and DNA (blue). Images are representative of three independent experiments. Scale bar= 5 μm. d, e Catenation
spread assay analysis. d DLD1 cells induced to express GFP-TopoIIα wild type or mutants were scored for the per cent joined (catenated) chromatids. The
mean ± SEM of three experiments where ≥15 cells per experiment were analysed is represented by the graph. (two-tailed Students’ t test; *P= 0.047;
siControl 43.38% ± 8.22, siTopoIIa 78.64% ± 6.61, WT 55.88% ± 4.58, S29A 69.24% ± 0.36, T1460A 72.07% ± 7.94, S29/T1460A 83.17% ± 12.49).
e HEK293 cells induced to express GFP-TopoIIa wild type or mutants were scored for the per cent joined (catenated) chromatids. The mean ± SEM of three
experiments where ≥15 cells per experiment were analysed is represented by the graph (two-tailed Students’ t test; ****P=≤0.0001; siControl 25.66% ±
6.17, siTopoIIa 99.57% ± 0.26, WT 25.62% ± 3.63, S29A 90.68% ± 4.44, T1460A 83.21%± 8.47, S29/T1460A 90.46%± 4.25).
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to assay. Cells were treated with inhibitors for the time/s stated. Cell lines were
routinely tested for mycoplasma. For cell synchronisation, cells were treated with a
double thymidine block (2.5 mM), released into pre-warmed, complete media for 6
h and arrested in G2/M by adding 9 µM RO-3306 (CDK1 inhibitor) and 1 µM
ICRF193. Cells were released into mitosis by washing with complete media and the
indicated inhibitors and monitored until they reached mitosis.
Plasmids. GFP-PKCε and TopoIIα-GFP (a kind gift from Dr Christian Mielke)
cDNAs were cloned into pcDNA5/FRT/TO(Invitrogen) using the InFusion cloning
kit (Clontech) as per the manufacturers’ instructions. For recombinant protein
production, pET-Duet-1 Aurora B:INCENP was a gift from Dr Jon Elkins, Uni-
versity of Oxford. Site-directed mutagenesis was completed using ChangeIT
mutagenesis kit (Agilent) according to the manufacturers’ instructions. All clones
were sequence verified.
Primers. See supplementary methods (Supplementary Tables 1–3) for full list of
primers used in this study.
siRNA. For siRNA transfection, Lullaby (OZ Biosciences) was used according to
manufacturers’ recommendations; all siRNAs were used at a final concentration of
20 nM. The following SmartPOOLS were purchased from Dharmacon:
PKCε si1 (D-004653-01 5′-GGGCAAAGAUGAAGUAUAU-3′), Caspase-3 (Cat.
L-004307 5′-CCGACAAGCUUGAAUUUAU-3′, 5′-CCACAGCACCUGG
UUAUUA-3′, 5′-GAAUUGAUGCGUAGAUGUUU-3′, 5′-GCGAAUCAAUGG
ACUCUGG-3′) and Caspase-7 (L-004407 5′-GGGCAAAUGCAUCAUAAUA-3′,5′
GAUCAGGGCUGUAUUGAAG-3′,5-UACCGUCCCUCUUCAGUAA-3′, 5′-CCA
GACCGGUCCUCGUUUG-3′). siTopoIIα(5′-GGUAACUCCUUGAAAGUAA-3′,
5′-GGAGAAGAUUAUACAUGUA-3′,5′-GAUGAACUCUGCAGGCUAA-3′, 5′
CGAAAGGAAUGGUUAACUA-3′) and siAuroraB (5′- AATTAGGGATCCCT
TCTTTCC-3′) were designed against the respective 3′ UTR to allow knockdown of
endogenous protein with expression of ectopic GFP-tagged proteins. The remaining
siControl oligonucleotides were purchased from Qiagen; cat. 1027310 (5′-AATTCT
CCGAACGTGTCACGT-3′).
Kinase assay. Kinase assays were conducted in 50 μl reactions containing 20mM
Tris pH7.5, 5mM MgCl2, 0.5mM DTT, 0.2% Triton X-100, 100 μM ATP. Reactions
were incubated for 30min at 37 °C using 100ng-1 μg of each recombinant protein
per reaction. Reactions were terminated by addition of NuPAGE 4× LDS sample
buffer (Thermo Fisher Scientific) prior to SDS–PAGE and western blotting with
the appropriate phospho antibodies to detect kinase activity against specific phospho-
sites. GFP-PKCε proteins were immunoprecipitated from DLD1 cells and ATP
consumption was measured by Kinase-GLO™ as per manufacturer’s instructions.
Peptide array. 15 mers of TopoIIα with a shift of two were arrayed on nitro-
cellulose by the Peptide Chemistry Laboratory of the Francis Crick Institute.
Membranes were blocked in 0.2 mg per ml BSA, 20 mM Tris pH 7.5, and 0.02%
Tween-20 overnight. Membranes were subsequently incubated with the appro-
priate recombinant protein (Aurora B Wild type (100 μg), Aurora B S227A
(100 μg)), and 10 mMMgCl2, 100 μM[32 P]-ATP (5μCi per ml) for 10 min followed
by extensive washing in H2O and acetic acid. Membranes were then exposed to
film before spot intensity analysis using the ImageQuant TL7 (GE Lifesciences).
Chromatin fractionation. Cells were swelled in a hypertonic buffer (10 mM Tris
pH7.5, 5 mM MgCl2, 1 mM EGTA, 1 mM DTT) for 20 min on ice before being
lysed by 20 strokes through a 25 G needle. The supernatant (S1) was collected as
the cytosolic fraction and the pellet was lysed in 1% Triton X-100 buffer (1% Triton
X-100, 150 mM NaCl, 50 mM Tris pH7.4, protease inhibitor cocktail (Roche)) for
10 min on ice before separating the supernatant (S2) and chromatin containing
pellet (P1) by high-speed centrifugation (15,000 × g, 20 min).
Triton X-100 fractionation. Cells were lysed in 5x pellet volumes of 1% Triton X-
100 buffer (1% Triton X-100, 150mM NaCl, 50mM Tris pH7.4, protease inhibitor
cocktail (Roche)) for 10min on ice before centrifugation (13,000 × g, 10min). The
pellet was resuspended in 2X NuPAGE LDS sample buffer (Thermo Fisher Scientific).
Immunofluorescence and immunoblotting. For immunofluorescence experi-
ments, cells were grown on 13mm, #1.5 glass coverslips and fixed in 4%
paraformaldehyde-PBS for 20 min, followed by permeabilization in 0.5% Triton X-
100 for 5 min before blocking in a solution of 3% BSA/PBS. The following primary
antibodies were used in these assays: mouse anti-TopoIIα (MAB4197, Millipore
1:300), rabbit anti-TopoIIα phosphoSer29 (made in-house, 1:100), rabbit anti-
TopoIIα phosphoThr1460 (made in-house, 1:100), mouse anti-alpha tubulin (clone
DM1A, T9026, Sigma, 1:1000), rabbit anti-PICH (H00054821-D01, Abnova,
1:300), mouse anti-Lap2B (611000, BD, 1:300), rabbit anti-Bub1 (Abcam, 1:100),
rabbit anti-BubR1 (Abcam, 1:300), rabbit anti-MAD2 (Bethyl Antibodies, 1:300),
human anti-centromere (Crest) (Antibodies Inc 1:300). Primary antibodies were
detected with Alexa Fluor conjugated secondary antibodies diluted 1:1000 in 3%
BSA/PBS (Goat anti-mouse AlexaFluor 488—A11001; Goat anti-rabbit AlexaFluor
488—A11008; Goat anti-mouse AlexaFluor 555—A21422; Goat anti-rabbit Alex-
aFluor 555 Conjugated secondary antibody—A21428; Goat anti-mouse AlexaFluor
647—A32728; Goat anti-rabbit AlexaFluor 647—A21244; Goat anti-human Alex-
aFluor 647—A21445, Life technologies). All coverslips were mounted using Pro-
Long Diamond with DAPI (Invitrogen).
For immunoblotting, cells were lysed in 1X NuPAGE LDS sample buffer
(Thermo Fisher Scientific) and sonicated for 3 × 10 s on ice. Proteins were
separated by SDS–PAGE and transferred to PVDF membranes (Millipore). The
following primary antibodies were used: mouse anti-Aurora B (AIM-1,611082, BD,
1:2000), rabbit anti-Aurora B phosphoThr232 (TA319253, Origene, 1:1000), rabbit
anti-Aurora B phosphoSer227 (made in-house, 1:1000), mouse anti-alpha tubulin
(clone DM1A, T9026, Sigma, 1:10000), mouse anti-TopoIIα (clone KiS1,
MAB4197, Millipore 1:5000), rabbit anti-TopoIIα phosphoSer29 (made in-house,
1:1000), rabbit anti-TopoIIα phosphoThr1460 (made in-house, 1:1000), rabbit
anti-Histone H3 (9715, Cell Signaling, 1:5000), rabbit anti-Histone H3
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Fig. 6 Working model of non-canonical PKCε signalling in response to excess metaphase catenation. In mitosis, Aurora B switches substrate specificity
in response to phosphorylation of S227 in the activation loop by a cell cycle-processed active fragment of PKCε. Here, we show that this switch protects
from chromosome non-disjunction by delaying anaphase entry and promoting TopoIIα-dependent resolution.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15163-6
12 NATURE COMMUNICATIONS |         (2020) 11:1396 | https://doi.org/10.1038/s41467-020-15163-6 | www.nature.com/naturecommunications
phosphoSer10 (9701, Cell Signaling, 1:2000), rabbit anti-PKCε (sc-214, Santa Cruz,
1:1000), rabbit anti-PKCε phosphoSer729 (ab63387, Abcam 1:1000), rabbit anti-
PKCε phosphoThr566 (made in-house, 1:500), rabbit anti-PKCε phosphoThr710
(made in-house, 1:500), mouse anti-GFP (made in-house, 1:1000), rabbit anti-
Caspase-3 (AB1899, Millipore, 1:500), mouse anti-Caspase-7 (551238, BC
Biosciences, 1:1000), mouse anti-GAPDH (clone 6C5, MAB374, Millipore, 1:5000),
anti-cleaved PARP Asp241 (9541, Cell Signaling, 1:500). Mouse and rabbit HRP-
conjugated secondary antibodies (NA931 and NA934, GE Lifesciences) were used
at dilutions between 1:5000 and 1:10000. Chemiluminescence was detected using
Lumanata Classico western HRP substrate (Millipore) and imaged using the
ImageQuant 4000 mini (GE Lifesciences). Band densitometry was carried out using
ImageJ software and normalised to a loading control. Uncropped western blots are
provided as Supplementary Fig. 9.
Proximity ligation assay. Cells were grown in eight-well chambered slides (Fal-
con) and fixed as for immunofluorescent imaging. PLA was conducted using a kit
(Sigma-Aldrich) as per manufacturers instruction using the antibody pairs: anti-
GFP (rabbit)(Abcam, ab290), anti-TopoIIα (mouse)(Millipore) and anti-TopoIIα,
anti-TopoIIα phospho-T1460 (rabbit)(made in-house). Non-specific IgG (rabbit
sc-2027 and mouse sc-2025, Santa Cruz) were used in conjunction with anti-
TopoIIα and anti-TopoIIα phospho-T1460 (respectively) as negative controls to
demonstrate the specificity of the PLA reaction.
Microscopy. For live-cell time-lapse microscopy, cells were cultured on LabTek
chambered coverglass slides (Nunc) in Leibovitz CO2-independent media (Thermo
Fisher Scientific). A low light level inverted microscopy (Nikon TE2000) imaging
system equipped with a laminar-flow heater to maintain a constant temperature of
37 ± 0.001 °C, a PlanFluor 40′ DIC lens and a Xenon lamp for fluorescent excita-
tion. Images were taken using a high quantum efficiency CCD camera (Andor
Ixon) every 5 min using MetaMorph (Version 6.3) software. Still images were taken
using an inverted laser scanning confocal microscope (Carl Zeiss LSM780)
equipped with a 63′ Plan-APOCHROMAT DIC oil-immersion objective using
ZEN (Version 2.3 SP1) software. Images were prepared for publication using
ImageJ software.
Catenation spread assay. For measurement of metaphase catenation, cells were
treated with siSgo1 for 24 h, followed by 1 h treatment with nocodazole to collapse
the mitotic spindle, to aid spreading. Cells were collected by shaking off the mitotic
cells and resuspended in a hypotonic solution of 75mM KCl and incubated at 37 °C
for 30 min to expand the cell. Cells were then resuspended in 3:1 methanol:acetic
acid and fixed overnight at −20 °C. Cells were then spread onto glass slides by
dropping from 1m height. For assays where TopoIIα was reintroduced, recombi-
nant TopoIIα (1 U/µl, TopoGen) was incubated in the hypotonic step where the cell
membrane becomes hyperpermeable. The hypotonic buffer used here contained 5
mM Tris-Cl, pH 8.0, 75mM KCl, 10mM MgCl2, 0.5 mM ATP, 0.5mM dithio-
threitol. We confirmed by video microscopy that there was no significant difference
between the time that all samples had been arrested in mitosis at the start of the
assay. Images processed using ImageJ software, and scored manually after blinding.
Immunofluorescent intensity profiles. TopoIIα pS29 signal intensity was quan-
tified using a custom-built script and the commercial software package MATLAB
(MATLAB 2016a, MathWorks). The background pS29 signal for each cell was
subtracted and the mitotic chromosomes were segmented by Otsu’s method of
thresholding of the DAPI channel. Subsequently, the pS29 signal intensity was
normalized to the DAPI signal intensity and DAPI area to account for potential
differences in chromatin condensation. At least ten images were analysed and the
mean and S.E.M. of at least three independent experiments was quantified.
Expression and purification of recombinant protein. Recombinant Aurora B
(WT and S227A) and PKCε-kinase domain were expressed and purified as pre-
viously described4. Aurora B WT and S227A proteins were assessed for their
phosphorylation state (pS227 and pT232) and kinase activity against the substrate
Histone H3 S10 prior to use in all assays. Upon highly efficient production (i.e.,
high concentration) both sites become phosphorylated in vitro.
Kinetoplast DNA decatenation assay. For in vitro assessment of TopoIIα dec-
atenation efficiency, the TopoGEN kinetoplast DNA (kDNA) assay was utilised
with the following deviations to the manufacturers’ instructions. Recombinant
TopoIIα was incubated with recombinant Aurora B WT (pS227/pT232) or Aurora
B S227A (pT232) at 30 °C for 30 min. Reactions contained 0.1 U recombinant
TopoIIα, 50 ng of recombinant Aurora B, 100 nM ATP, and 1X reaction buffer
(Topogen) made up to 20 µl with kinase dilution buffer. Reactions were terminated
by addition of DNA gel loading dye (Thermo Fisher). kDNA was separated by
electrophoresis on 1% agarose gel containing GelRed™ fluorescent DNA stain.
Images were captured on UVP BioDoc-It2 imaging system using VisionWorks
analysis software (Analytik Jena), and the kDNA decatenation quantified by cal-
culating band densitometry using ImageJ analysis software.
TopoIIα extraction and decatenation assay. HEK293 cells were induced to
express GFP-TopoIIα for 24 h while endogenous TopoIIα was depleted with
siRNA. Cells were twice pelleted and resuspended in ice-cold TEMP buffer (10 mM
Tris pH7.5, 1 mM EDTA, 4 mM MgCl2, 0.5 mM PMSF) before being left on ice for
10 min. Lysates were homogenised by ten strokes through a 25 G needle before
nuclei were pelleted by centrifugation (1500 × g, 10 min). The nuclear pellet was
resuspended in TEMP buffer and washed, then resuspended in 4 pellet volumes of
TEP buffer (10 mM Tris pH7.5, 1 mM EDTA, 0.5 mM PMSF) and an equal volume
of 1M NaCl added. Preparations were vortexed and left on ice for 60 min. Finally,
nuclear preparations were centrifuged at 4 °C for 15 min at 15,000 × g. Super-
natants were diluted with 4X NuPAGE LDS sample buffer and immunoblotted for
TopoIIα levels. TopoIIα levels were equalised prior to use in the TopoGEN kine-
toplast DNA assay as above.
Recapitulating PKCε cleavage. To assess the effect of recapitulating PKCε cleavage
on the metaphase–anaphase transition time, DLD1 GFP-PKCε TEV D383/451N
expressing pmCherry-H2B cells were transfected with siPKCε, after 24 h doxycycline
(100 ng/ml) was added and incubated at 37 °C and 10% CO2 for 16 h. Cells were
incubated for 3 h with 500 nM nocodazole to arrest the cells in prometaphase, fol-
lowed by a further 2-h incubation with 100 ng rapamycin/ml to drive chemically
induced dimerisation of TEV, and, as a result, PKCε cleavage. Media were aspirated
and cells were washed three times with pre-warmed media to release the prometa-
phase arrest. Media were then replaced with 500 µl Leibovitz CO2-independent
media (Gibco) ± 1 µM ICRF193. Live-cell time-lapse images were obtained as above.
Homology modelling. The enzyme structure was obtained by homology modelling
using SwissModel web server with the same amino acid sequence with two different
templates of 4AF3 with 99.69% sequence identity and 5 × 3 F with 31.91% sequence
identity to the target amino acid sequence with Uniprot FASTA code Q96GD4. The
obtained model using 4AF3 as the template excludes the N-terminal and the second
model was applied to amend the structure of the enzyme. The generated enzyme
structure was considered in the presence of IN-box segment of INCENP, ATP, and
MG2+ ions in two separate states of mono- and bis-phosphorylated forms by phos-
phorylation of Thr232 and Ser277 residues located in the loop (residues 220–250).
Molecular dynamics simulations for dominant conformations. A total of 100-ns
molecular dynamics simulations by AMBER 16 were performed for each system after
minimising them with and without restraint. This was done in two stages with 2500
cycles of steepest descent followed by 2500 cycles of conjugate gradient minimisation
and heating up to 310 K within 500 ps and equilibrating for 1 ns using. The cutoff
radius of non-covalent interactions was set to 12 Å. Also, periodic boundary condi-
tions, particle-mesh Ewald method, to calculate the infinite electrostatics without
truncating the parameters, and SHAKE algorithm, to consider all bonds in which the
hydrogen atom was present in a fixed state and the others in their equilibrium values,
were employed. The force fields parameters for the phosphorylated amino acids were
generated using the ANTECHAMBER module of the AMBER program. Ten domi-
nant conformation structures after downsampling of the obtained MD trajectories
were extracted using MDAnalysis to run molecular docking.
Peptide–protein molecular docking. To complement the experimental char-
acterisation of the protein–peptide complexes, we determined the peptide binding
site in the protein and mode of interaction between the peptides and their corre-
sponding protein kinase in the mono- and bis-phosphorylated states of Aurora B
kinase using HPEPDOCK web server and Pep-SiteFinder service to run
peptide–protein molecular docking and finding the key residues respectively. The
peptide containing TopoIIα T1460 residue (QKPDPAKTKNRRKRKP) and
TopoIIα S29 peptide (NEDAKKRLSVERIYQKK) were considered as the peptide
substrates for monophosphorylated (pT232) and bis-phosphorylated (pS227/
pT232) forms of the enzyme, respectively.
Molecular dynamics simulations of protein–peptide complexes. A total of 100
ns molecular dynamics simulations by AMBER 16 were performed for the best
poses of the peptides, located in the localised binding site by the above approaches,
in complex with the enzymes. The parameters were considered as mentioned in the
first round of MD simulations performed to extract the dominant conformations of
mono and bis-phosphorylated Aurora B kinase.
Principal component analysis (PCA). PCA has been used to investigate the
correlations among various important regions of the complexes in the course of
MD simulations and to distinguish functional motions from the thermal and
accidental motions. The fluctuations of the residues in critical regions were
monitored using three different modes of PCA (PC1, PC2, and PC3).
Statistical analysis. For experiments where the data includes more than two
conditions, a one-way ANOVA using multiple comparisons was used, in all other
cases an unpaired t test was used for analysis. Prism software (Graphpad) was used
for all calculations. The level of statistical significance is represented as follows:
ns= P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request.
Code availability
Custom code developed for the immunofluorescence intensity profiling is available upon
request.
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